Biomarkers and updates on pediatrics lupus nephritis

Rheum Dis Clin North Am. 2013 Nov;39(4):833-53. doi: 10.1016/j.rdc.2013.05.001. Epub 2013 Jul 16.

Abstract

Lupus nephritis is a common complication of systemic lupus erythematosus in children and adolescents. This article reviews the clinical relevance of lupus nephritis and its current treatment. The reader is introduced to novel biomarkers that are expected to improve the management of lupus nephritis in the future, and support the testing of novel medication regimens.

Keywords: Biomarkers; Childhood-onset SLE; Lupus nephritis; Systemic lupus erythematosus; Treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute-Phase Proteins / urine
  • Biomarkers / urine
  • Biopsy
  • Chemokine CCL2 / urine
  • Child
  • Complement C4 / urine
  • Cytokine TWEAK
  • Glucocorticoids / therapeutic use
  • Hepcidins / urine
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / prevention & control*
  • Lipocalin-2
  • Lipocalins / urine
  • Lupus Nephritis / complications
  • Lupus Nephritis / diagnosis*
  • Lupus Nephritis / drug therapy
  • Proteinuria / etiology
  • Proto-Oncogene Proteins / urine
  • Tumor Necrosis Factors / urine

Substances

  • Acute-Phase Proteins
  • Biomarkers
  • CCL2 protein, human
  • Chemokine CCL2
  • Complement C4
  • Cytokine TWEAK
  • Glucocorticoids
  • Hepcidins
  • Immunosuppressive Agents
  • LCN2 protein, human
  • Lipocalin-2
  • Lipocalins
  • Proto-Oncogene Proteins
  • TNFSF12 protein, human
  • Tumor Necrosis Factors